Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
16Lindenbaum J, Healton EB, Savage DG, et al
Keto diets can produce similar unwanted issuesthe keto flu is known for afflicting those adjusting to ketosis for the first time, and can come with many of the same symptoms as semaglutide, such as nausea or constipation
With 101 million people living with diabetes and another 136 million in the prediabetic stage, India is fast emerging as a key market for GLP-1 agonist therapies
Advanced Japanese Formula: Unique Manufacturing: Discuss the innovative lyophilized (freeze-dried) process that enhances the purity and potency of the Glutathione used in the injections
Regular monitoring and lifestyle guidance ensure that each patient receives safe, supportive care throughout their treatment journey